SCHEMBL24036739

SCHEMBL24036739

COC(=O)C[C@H](N[S@+]([O-])C(C)(C)C)c1cc(F)cc(C(F)(F)F)c1

nearest known ligand 0.36

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR2 P25025 2/20 0.36
AKT1 P31749 2/20 0.36
RPS6KB1 P23443 1/20 0.34
ITGB3 P05106 1/20 0.34
ITGB1 P05556 1/20 0.34
ITGAV P06756 1/20 0.34
ITGA5 P08648 1/20 0.34
ITGB5 P18084 1/20 0.34
ITGB6 P18564 1/20 0.34
ITGB8 P26012 1/20 0.34
ITGA8 P53708 1/20 0.34
CETP P11597 6/20 0.33
KCNH2 Q12809 3/20 0.33
SCN9A Q15858 1/20 0.32
HTT P42858 2/20 0.32
ALDH1A1 P00352 1/20 0.32
MAPT P10636 1/20 0.32
CTSA P10619 1/20 0.32
CYP3A4 P08684 1/20 0.31
EEF2K O00418 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL25753562 1.00 CXCR2 (0.36) CXCR2AKT1RPS6KB1ITGB3ITGB1
SCHEMBL25753566 0.93 TACR1 (0.34) CETPALDH1A1MAPTCTSAEEF2K
SCHEMBL25622767 0.93 TACR1 (0.34) CETPALDH1A1MAPTCTSAEEF2K
SCHEMBL24036736 0.93 TACR1 (0.34) CETPALDH1A1MAPTCTSAEEF2K
SCHEMBL24036735 0.89 CETP (0.32) CETPALDH1A1EEF2K
SCHEMBL24036737 0.89 CXCR2 (0.36) CXCR2HTTALDH1A1MAPTCTSA
SCHEMBL25753553 0.89 CXCR2 (0.36) CXCR2HTTALDH1A1MAPTCTSA
SCHEMBL25753551 0.89 CETP (0.32) CETPALDH1A1EEF2K
SCHEMBL30388831 0.88 SLC13A3 (0.35) CETPMAPTCTSAEEF2KKLRK1
SCHEMBL25622766 0.88 RXRA (0.37) CETPSCN9AHTTCTSARXRA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230192661-A1 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE UBE CORPORATION (JP) 2023-06-22 US disclosed
US-20230192661-A1 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE UBE CORPORATION (JP) 2023-06-22 US disclosed
WO-2023085396-A1 PHARMACEUTICAL COMPOSITION FOR PROVIDING TREATMENT FOR OR PREVENTING ALPORT SYNDROME UBE株式会社 2023-05-19 WO disclosed
WO-2021230325-A1 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE 宇部興産株式会社 2021-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230192661-A1 1, 4, 5, 6-TETRAHYDROPYRIMIDINE-2-AMINE DERIVATIVE DHFR, DPYD, CYP2D6 CXCR2 1259/4885AKT1 1720/4885RPS6KB1 973/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.